Image acquisition and interpretation of 18F-DCFPyL (piflufolastat F 18) PET/CT: How we do it

Prostate cancer is the second most common malignancy in men with more than one million new cases diagnosed worldwide each year.1 Accurate diagnostic imaging for staging and re-staging of men with prostate cancer is paramount and this need has recently been at least partly addressed by the widespread adoption of center, registration trials, OSPREY (patient population: highrisk primary staging) and CONDOR (patient population: biochemical recurrence). In this manuscript, we will (1) review key findings from the OSPREY and CONDOR trials, (2) discuss the clinical acquisition protocol we use for 18F-DCFPyL PET scanning, (3) present information on important pearls and pitfalls, (4) provide an overview of the PSMA reporting and data system (PSMA-RADS) interpretive framework, and (5) posit important future directions for research in PSMA PET.